

# Thierry Lave

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11620332/publications.pdf>

Version: 2024-02-01

41  
papers

2,950  
citations

159358

30  
h-index

276539

41  
g-index

46  
all docs

46  
docs citations

46  
times ranked

2021  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2006, 45, 511-542.	1.6	301
2	PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessment of prediction methods of human clearance. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4090-4110.	1.6	165
3	Prediction of intestinal absorption: comparative assessment of gastropluâ„¢ and ideaâ„¢. <i>European Journal of Pharmaceutical Sciences</i> , 2002, 17, 51-61.	1.9	159
4	PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentrationâ€”time profiles in human by using the physiologicallyâ€”based pharmacokinetic modeling approach. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4127-4157.	1.6	152
5	Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations. <i>Clinical Pharmacokinetics</i> , 1999, 36, 211-231.	1.6	141
6	Predicting Pharmacokinetic Food Effects Using Biorelevant Solubility Media and Physiologically Based Modelling. <i>Clinical Pharmacokinetics</i> , 2006, 45, 1213-1226.	1.6	131
7	Applications of Physiologically Based Absorption Models in Drug Discovery and Development. <i>Molecular Pharmaceutics</i> , 2008, 5, 760-775.	2.3	107
8	PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4074-4089.	1.6	105
9	An Evaluation of the Utility of Physiologically Based Models of Pharmacokinetics in Early Drug Discovery. <i>Journal of Pharmaceutical Sciences</i> , 2005, 94, 2327-2343.	1.6	100
10	Development of a Physiologically Based Model for Oseltamivir and Simulation of Pharmacokinetics in Neonates and Infants. <i>Clinical Pharmacokinetics</i> , 2011, 50, 613-623.	1.6	100
11	Design, Data Analysis, and Simulation of in Vitro Drug Transport Kinetic Experiments Using a Mechanistic in Vitro Model. <i>Drug Metabolism and Disposition</i> , 2008, 36, 2434-2444.	1.7	92
12	Application of Full Physiological Models for Pharmaceutical Drug Candidate Selection and Extrapolation of Pharmacokinetics to Man. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005, 96, 193-199.	1.2	91
13	Ethyl methanesulfonate toxicity in Viraceptâ€”A comprehensive human risk assessment based on threshold data for genotoxicity. <i>Toxicology Letters</i> , 2009, 190, 317-329.	0.4	85
14	Prediction of Hepatic Metabolic Clearance. <i>Clinical Pharmacokinetics</i> , 2001, 40, 553-563.	1.6	79
15	Combining in Vitro and in Vivo Pharmacokinetic Data for Prediction of Hepatic Drug Clearance in Humans by Artificial Neural Networks and Multivariate Statistical Techniques. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 5072-5076.	2.9	76
16	Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009, 36, 585-611.	0.8	75
17	Influence of isolation procedure, extracellular matrix and dexamethasone on the regulation of membrane transporters gene expression in rat hepatocytes. <i>Biochemical Pharmacology</i> , 2002, 64, 1637-1650.	2.0	74
18	Physiologically Based Pharmacokinetic (PBPK) Modeling of Disposition of Epiroprim in Humans. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 1990-2007.	1.6	67

#	ARTICLE	IF	CITATIONS
19	Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: Influence of time between substrate and inducer administration. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 56, 1-15.	1.9	65
20	Physiologically-based Kinetic Modelling (PBK Modelling): Meeting the 3Rs Agenda. <i>ATLA Alternatives To Laboratory Animals</i> , 2007, 35, 661-671.	0.7	59
21	Prediction of hepatic clearance using cryopreserved human hepatocytes: a comparison of serum and serum-free incubations. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 58, 633-641.	1.2	57
22	Mechanistic Modeling of Hepatic Transport from Cells to Whole Body: Application to Napsagatran and Fexofenadine. <i>Molecular Pharmaceutics</i> , 2009, 6, 1716-1733.	2.3	56
23	PhRMA CPCDC Initiative on Predictive Models of Human Pharmacokinetics, Part 1: Goals, Properties of the Phrma Dataset, and Comparison with Literature Datasets. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4050-4073.	1.6	55
24	Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 23, 189-199.	1.9	52
25	Interspecies Pharmacokinetic Comparisons and Allometric Scaling of Napsagatran, a Low Molecular Weight Thrombin Inhibitor. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 51, 85-91.	1.2	51
26	PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4111-4126.	1.6	51
27	Human clearance prediction: shifting the paradigm. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 1039-1048.	1.5	44
28	Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3144-3156.	1.4	41
29	Cryopreserved human hepatocytes in suspension are a convenient high throughput tool for the prediction of metabolic clearance. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2006, 63, 347-355.	2.0	37
30	Interspecies scaling of bosentan, a new endothelin receptor antagonist and integration of in vitro data into allometric scaling. <i>Pharmaceutical Research</i> , 1996, 13, 97-101.	1.7	36
31	Animal Pharmacokinetics and Interspecies Scaling from Animals to Man of Lamifiban, a New Platelet Aggregation Inhibitor. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 48, 573-577.	1.2	35
32	Interspecies Scaling of Interferon Disposition and Comparison of Allometric Scaling with Concentration-Time Transformations. <i>Journal of Pharmaceutical Sciences</i> , 1995, 84, 1285-1290.	1.6	34
33	Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development. <i>Journal of Pharmacological and Toxicological Methods</i> , 2014, 70, 73-85.	0.3	30
34	Mass Spectrometry-Based Quantification of CYP Enzymes to Establish In Vitro/In Vivo Scaling Factors for Intestinal and Hepatic Metabolism in Beagle Dog. <i>Pharmaceutical Research</i> , 2012, 29, 1832-1842.	1.7	29
35	Translational PK/PD modeling to increase probability of success in drug discovery and early development. <i>Drug Discovery Today: Technologies</i> , 2016, 21-22, 27-34.	4.0	27
36	Prediction of Pharmacokinetic Profile of Valsartan in Humans Based on <i>in vitro</i> Uptake-Transport Data. <i>Chemistry and Biodiversity</i> , 2009, 6, 1975-1987.	1.0	18

#	ARTICLE	IF	CITATIONS
37	In vivo and in vitro characterization of ethyl methanesulfonate pharmacokinetics in animals and in human. Toxicology Letters, 2009, 190, 303-309.	0.4	18
38	Importance of target-mediated drug disposition for small molecules. Drug Discovery Today, 2018, 23, 2023-2030.	3.2	15
39	Modelling of patient EMS exposure: Translating pharmacokinetics of EMS in vitro and in animals into patients. Toxicology Letters, 2009, 190, 310-316.	0.4	13
40	Risk Assessment in Extrapolation of Pharmacokinetics from Preclinical Data to Humans. Clinical Pharmacokinetics, 2010, 49, 619-632.	1.6	10
41	Interspecies Scaling. , 2004, , 133-175.		3